News >

Encorafenib/Binimetinib Combo Continues to Show Survival Benefit in BRAF-Mutant Melanoma

Ellie Leick
Published: Tuesday, Sep 03, 2019

Keith Flaherty, MD

Keith T. Flaherty, MD

Long-term data from the COLUMBUS trial showed that encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival (OS) and progression-free survival (PFS) compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.

At a median follow-up of 48.8 months, the updated results, which were presented at the 2019 ASCO Annual Meeting, demonstrated that the median OS was 33.6 months for encorafenib/binimetinib, 23.5 months for encorafenib alone, and 16.9 months for vemurafenib alone. Overall, the combination decreased the risk of death by 39% versus vemurafenib alone (HR, 0.61; 95% CI, 0.48-0.79). Additionally, the median progression-free survival (PFS) was 14.9 months for encorafenib/binimetinib, 9.6 months for encorafenib alone, and 7.3 months for vemurafenib alone.

In June 2018, the FDA approved the combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test, based on earlier COLUMBUS data.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x